Substance / Medication

Perindopril erbumine

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
Comparative study of Mg/Al- and Zn/Al-layered double hydroxide-perindopril erbumine nanocomposites for inhibition of angiotensin-converting enzyme.
Hussein Al Ali Samer Hasan, Al-Qubaisi Mothanna, Hussein Mohd Zobir et al. · Int J Nanomedicine · 2012
PMID: 22904631ObservationalFull text (PMC)
Bioequivalence study of two perindopril erbumine tablet formulations in healthy volunteers.
Setiawati Effi, Deniati Siti Hawa, Yunaidi Danang Agung et al. · Arzneimittelforschung · 2011
PMID: 21650082Observational
Stability-indicating RP-HPLC method for the quantitative analysis of perindopril erbumine in tablet dosage form.
Dugga Hari Hara Theja, Peraman Ramalingam, Nayakanti Devanna · J Chromatogr Sci · 2014
PMID: 23690066Other
Dissolving microneedle patch for transdermal delivery of perindopril erbumine.
Altaf Zunaira, Ahmad Zulcaif, Mahmood Asif et al. · Inflammopharmacology · 2025
PMID: 40009346Preclinical
Perindopril erbumine-entrapped ultradeformable liposomes alleviate sarcopenia via effective skin delivery in muscle atrophy mouse model.
Choi Ho-Ik, Ryu Jeong-Su, Noh Ha-Yeon et al. · Int J Pharm · 2024
PMID: 39489388Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Perindopril erbumine (substance)
SNOMED CT
129485000
UMLS CUI
C0244718

Clinical Data

This intervention maps to 10 entities in the Healos knowledge graph.

3
Conditions
4
Biomarkers
2
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.